Dec. 2006 / Jan. 2007
PerkinElmer announced its acquisition of Evotec Technologies in a €23 million deal ($30.5 million). Evotec Technologies provides high-performance screening instrumentation and analysis software including the Opera HCS platform. PerkinElmer will offer these tools to its pharmaceutical and biotechnology customers for mapping cellular events.
Galapagos, based in Belgium, has entered a definitive agreement to acquire the U.K. informatics company Inpharmatica in an all-share deal worth €12.5 million euros ($16.6 million). The deal is expected to be complete in March 2007.
Sylva Collins has joined Cincinnati-based Kendle International as vice president, biometrics. Formerly vice president, global electronic data management at Novartis, Collins (see "Master of the EDC Universe," Bio-IT World, August 2004, pp: 26-28) will oversee Kendle's global biometrics services including clinical data management, biostatistics, and scientific programming.
Ingenuity Systems announced a global licensing deal to provide Astellas Pharma with its Ingenuity Pathways Analysis (IPA) software and comprehensive database, the Ingenuity Pathways Knowledge Base.
AND FINALLY ...
Andrew von Eschenbach was confirmed as the new commissioner of the FDA. Von Eschenbach, who has served as acting commissioner since September 2005, was previously director of the National Cancer Institute and is an advocate of genomics technologies in drug discovery.